Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu dopisy, práce podpořená grantem
PubMed
35604280
PubMed Central
PMC10084376
DOI
10.1002/ajh.26602
Knihovny.cz E-zdroje
- MeSH
- dexamethason terapeutické užití MeSH
- humanizované monoklonální protilátky terapeutické užití MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie MeSH
- mnohočetný myelom * farmakoterapie MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- Názvy látek
- carfilzomib MeSH Prohlížeč
- dexamethason MeSH
- humanizované monoklonální protilátky MeSH
- isatuximab MeSH Prohlížeč
Departamento de Hematología Hospital 12 de Octubre Complutense University Madrid Spain
Department of Haematology General Hospital of Athens Athens Greece
Department of Haematology University College Hospital London UK
Department of Hemato Oncology Faculty of Medicine University of Ostrava Ostrava Czech Republic
Department of Hemato Oncology University Hospital Olomouc Olomouc Czech Republic
Department of Hemato Oncology University Hospital Ostrava Ostrava Czech Republic
Department of Hematology University Hospital Hôtel Dieu Nantes France
Hematology Department University Hospital La Fe Valencia Spain
Hospital de Cancer de Barretos São Paulo Brazil
Sanofi Cambridge Massachusetts USA
Sir Charles Gairdner Hospital Perth Western Australia Australia
The National and Kapodistrian University of Athens Athens Greece
Translational Genomics Research Institute City of Hope Cancer Center Phoenix Arizona USA
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California USA
Zobrazit více v PubMed
Raab MS, Fink L, Schoen P, et al. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. Br J Haematol. 2019;185(5):981‐984. PubMed
Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low‐dose dexamethasone versus pomalidomide and low‐dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA‐MM): a randomised, multicentre, open‐label, phase 3 study. Lancet. 2019;394(10214):2096‐2107. PubMed
Moreau P, Dimopoulos M, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open‐label, randomised phase 3 trial. Lancet. 2021;397(10292):2361‐2371. PubMed
Moreau P, Joshua D, Chng WJ, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31(1):115‐122. PubMed PMC
Quach H, Nooka A, Samoylova O, et al. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. Br J Haematol. 2021;194(4):784‐788. PubMed
Bringhen S, Pour L, Vorobyev V, et al. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA‐MM subgroup analysis. Leuk Res. 2021;104:106576. PubMed
